Jacobs Levy Equity Management Inc. Has $149.51 Million Stock Holdings in Humana Inc. (NYSE:HUM)

Jacobs Levy Equity Management Inc. boosted its position in shares of Humana Inc. (NYSE:HUM) by 0.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 589,287 shares of the insurance provider’s stock after purchasing an additional 1,615 shares during the period. Jacobs Levy Equity Management Inc. owned 0.49% of Humana worth $149,508,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Humankind Investments LLC grew its stake in shares of Humana by 32.6% in the 4th quarter. Humankind Investments LLC now owns 1,612 shares of the insurance provider’s stock valued at $409,000 after buying an additional 396 shares in the last quarter. Gotham Asset Management LLC grew its position in Humana by 38.9% in the fourth quarter. Gotham Asset Management LLC now owns 32,593 shares of the insurance provider’s stock worth $8,269,000 after acquiring an additional 9,132 shares in the last quarter. Ethic Inc. increased its stake in shares of Humana by 7.7% during the 4th quarter. Ethic Inc. now owns 8,641 shares of the insurance provider’s stock worth $2,192,000 after purchasing an additional 619 shares during the last quarter. Fred Alger Management LLC bought a new position in shares of Humana during the 4th quarter valued at $451,000. Finally, Family Management Corp acquired a new stake in shares of Humana in the 4th quarter valued at $3,134,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

NYSE:HUM opened at $249.67 on Friday. The company has a market capitalization of $30.13 billion, a price-to-earnings ratio of 25.09, a PEG ratio of 2.05 and a beta of 0.49. The company has a 50-day moving average of $265.21 and a 200-day moving average of $270.38. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. During the same period in the previous year, the business earned $7.23 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. As a group, equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.42%. Humana’s payout ratio is presently 25.04%.

Analyst Upgrades and Downgrades

Several equities analysts have commented on HUM shares. Robert W. Baird increased their target price on shares of Humana from $270.00 to $300.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 15th. StockNews.com upgraded Humana from a “hold” rating to a “buy” rating in a report on Friday. Piper Sandler boosted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Seventeen research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $287.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.